Antibody Response to a Single Dose of COVID Vaccine | CDC/FDA Updates | February 8, 2021
Date of Presentation: February 8, 2021
Type: Past Presentation
Audience: Clinical
Program: Virology
Keywords: #covid clinical updates #single dose #vaccine efficacy
In this series of presentations, Dr. Thomas Becker, Medical Epidemiologist and ECHO faculty member, discusses the evidence from recent research related to effectiveness of one dose of currently available COVID vaccines in different situations, and implications for patients and populations. Then, Eileen M. Dunne, PhD, Epidemic Intelligence Service Officer for the Centers for Disease Control and Prevention at the Idaho Division of Public Health and ECHO faculty member, provides a public health practice update and a number of valuable COVID-19 related resources produced by the CDC and FDA.
Recording:
Presented by:
Dr. Tom Becker, Dr. Eileen M. Dunne
Thomas Becker, MD, PhD, is a medical epidemiologist, and trained in internal medicine, anthropology, and public health; he began his career at the University of New Mexico before moving to the Northwest about 20 years ago. Since his arrival in Portland, Becker has worked with the Northwest Portland Area Indian Health Board and Oregon Health & Science University. He has published on a diverse range of American Indian health issues, including both infectious and chronic diseases. And with the Indian Health Board, he has been involved in etiologic studies, community prevention programs and education programs to improve career opportunities for people in tribes nationwide.
Eileen M. Dunne, PhD, is an Epidemic Intelligence Service Officer for the Centers for Disease Control and Prevention at the Idaho Division of Public Health, Bureau of Communicable Disease Prevention
Resources Provided:
- Antibody Response to a Single Dose of COVID Vaccine (Presentation Slides)
- Public Health Updates (Presentation Slides)
- The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection 13-24 Days After Immunization: real-world evidence (pre-print MedRxiv)
- Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2 (pre-print MedRxiv)
- Estimating the Effectiveness of the Pfizer COVID-19 BNT162b2 Vaccine After a Single Dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel (pre-print MedRxiv)
- Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21–65 Years in a Large Integrated Health Care System — Southern California, January 1–September 30, 2019, and January 1–September 30, 2020 (MMWR)
- Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021 (MMWR)
- Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021 (MMWR)
- Racial and Ethnic Disparities in the Prevalence of Stress and Worry, Mental Health Conditions, and Increased Substance Use Among Adults During the COVID-19 Pandemic — United States, April and May 2020 (MMWR)
- Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 (MMWR)
- mRNA-1273 Vaccine Induces Neutralizing Antibodies Against Spike Mutants from Global SARS-CoV-2 Variants (pre-print BioRxiv)
- Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine-elicited Human Sera (pre-print BioRxiv)
- Novavax Vaccine Trial Results Press Release (Novavax)
- Johnson & Johnson Vaccine Trial Results Press Release (J&J)
- Oxford Covid-19 Vaccine Trial Results (Univ of Witwatersrand Johannesburg)
- Danish scientists see tough times ahead as variant rises (Science Mag)
- Fast-spreading U.K. virus variant raises alarms (Science Mag)
- South Africa Pauses AstraZeneca Vaccine Rollout (CNN)
- HHS Amends PREP Act Declaration to Increase Workforce Authorized to Administer COVID-19 Vaccines (HHS)
- Announcement of NeuroCOVID (NIH)
- Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released (NIH)
- Advisory Committee Meeting to Discuss Janssen Biotech Inc.’s COVID-19 Vaccine Candidate (FDA)
- Face Mask Requirement for Transportation (CDC)
Date added: February 8, 2021